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Abstract
Background: In cancer studies, it is common that multiple microarray experiments are conducted
to measure the same clinical outcome and expressions of the same set of genes. An important goal
of such experiments is to identify a subset of genes that can potentially serve as predictive markers
for cancer development and progression. Analyses of individual experiments may lead to unreliable
gene selection results because of the small sample sizes. Meta analysis can be used to pool multiple
experiments, increase statistical power, and achieve more reliable gene selection. The meta analysis
of cancer microarray data is challenging because of the high dimensionality of gene expressions and
the differences in experimental settings amongst different experiments.
Results: We propose a Meta Threshold Gradient Descent Regularization (MTGDR) approach for
gene selection in the meta analysis of cancer microarray data. The MTGDR has many advantages
over existing approaches. It allows different experiments to have different experimental settings. It
can account for the joint effects of multiple genes on cancer, and it can select the same set of
cancer-associated genes across multiple experiments. Simulation studies and analyses of multiple
pancreatic and liver cancer experiments demonstrate the superior performance of the MTGDR.
Conclusion: The MTGDR provides an effective way of analyzing multiple cancer microarray
studies and selecting reliable cancer-associated genes.
Background
Microarrays are capable of profiling human tissues on a
genome-wide scale and have been used extensively in can-
cer studies, where expressions of thousands of genes are
measured along with clinical outcomes. A major goal of
such studies is to identify a subset of cancer-associated
genes that can be used as biomarkers for cancer diagnosis
and prognosis and as targets for therapy. Early studies
have shown that gene signatures identified from the anal-
ysis of individual cancer microarray experiments often
have low reproducibility. There are several reasons for
this. A main one is that the sample size of a single micro-
array experiment, which is usually in the hundreds, is
much smaller than the number of genes, which is usually
in the tens of thousands.
Within the field of clinical investigation, meta analysis has
emerged as the gold standard for the comparison and
combined analysis of clinical studies. It is generally
accepted that only meta analysis can circumvent the prob-
lems inherent to studies with low statistical powers due to
low sample sizes [1]. With meta analysis, it is usually not
the intention of researchers to analyze any new datasets.
Rather, it provides an effective way of pooling and analyz-
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ing multiple existing datasets and generating results more
reliable than those from the analysis of each individual
data set.
Meta analysis of cancer microarray data is made possible
by the many experiments conducted independently to
measure the same set of genes and the same cancer clinical
outcomes. As shown in [2-5], the meta analysis of cancer
microarray data has achieved considerable successes by
identifying relatively reproducible, biologically meaning-
ful gene signatures. We refer to [6] for more discussions of
the merits of meta analysis in genomic studies.
Meta analysis of cancer microarray data is challenging
because (1) microarray experiments usually measure a
small number of samples and a large number of genes,
with only a subset of those genes associated with cancer
clinical outcomes. Gene selection is needed along with
estimation; (2) the meta analysis of cancer microarray
data and the identification of cancer-associated genes
often require the use of original expression measure-
ments. For this reason, the type of analysis conducted in
this article has also been referred to as "integrative analy-
sis". Such analysis differs significantly from conventional
meta analysis, where the analysis is based on summary
statistics (such as p-values) from each individual experi-
ment; and (3) different platforms may be used in different
experiments. Arrays that hybridize one sample at a time
(e.g., synthesized oligonucleotide arrays) measure gene
expression based directly on the signal intensity of each
probe set. In contrast, spotted cDNA arrays hybridized
with fluorescent-labeled targets typically measure the
ratio of the signal from a test sample to the signal of a co-
hybridized reference sample. It has been shown that data
from Affymetrix GeneChip oligonucleotide microarrays
correlate poorly with the data from custom-printed cDNA
microarrays [7]. We note here that comparability of differ-
ent platforms can be achieved by the transformation of
the expressions. However, as noted in previous studies
(such as [8]), such transformation needs to be conducted
on a case-by-case basis.
Several approaches have been proposed to analyze the
marginal effects of genes using data from multiple micro-
array experiments. Examples of this include Fisher's
approach (with application to breast cancer [9]); an inten-
sity approach that transforms and directly integrates gene
expressions [5]; a penalization approach [3]; a random
effect model based approach [10]; a robust gene ranking
approach [11]; and a Bayesian approach [12].
In light of the fact that cancer development and progres-
sion are caused by the effects of multiple genes, the fol-
lowing studies (which can account for the joint effects of
genes) have been conducted. A majority voting (with
impact factors) approach has been proposed by [13].
Gene shaving approaches based on random forrest and
Fisher's linear discrimination are applied in [14]. And a
computationally intensive Bayesian approach is proposed
in [15]. We note that the focus of those studies has been
predictive model building, not gene selection.
On the other hand, there is rich literature for the analysis
of a single cancer microarray data and gene selection.
Examples include the parameterized classifier design
approach in [16]; the penalization approaches in [17,18];
the Threshold Gradient Directed Regularization (TGDR)
approach [19-21]; and the support vector machine
approach [22]. We refer to [23] for more discussions of
gene selection approaches with individual microarray
datasets. We note, however, that those approaches have
been designed to analyze a single dataset, and cannot be
used to analyze multiple, heterogeneous datasets.
The literature review suggests that (1) genes identified
from analysis of a single cancer microarray data may suffer
from low reproducibility because of the small sample size.
Meta analysis pools multiple datasets, increases statistical
power, and provides an effective way of improving repro-
ducibility; (2) existing meta analysis approaches focus on
either the investigation of the marginal effects of genes or
the construction of predictive models with multiple
genes; and (3) approaches exist that can select genes with
joint effects on cancer in the analysis of a single dataset.
However, these approaches cannot be used to analyze
multiple, heterogeneous data. Thus, there is a critical need
for approaches that can select genes with joint effects on
cancer in the meta analysis of multiple microarray data.
In this article, we propose the Meta Threshold Gradient
Descent Regularization (MTGDR) approach for gene
selection in cancer microarray meta analysis. The MTGDR
takes advantage of recent developments in regularized
gene selection with a single microarray dataset. Compared
to such single-dataset gene selection methods, the
MTGDR has the desired flexibility of accommodating
multiple experiments with different setups. And in com-
parison with the available meta analysis methods, the
MTGDR can effectively select a subset of genes with joint
effects on cancer.
Results and discussion
Simulation study
We conduct simulation studies to investigate the perform-
ance of the proposed MTGDR. We generate M = 3 datasets.
For dataset m = 1, 2 and 3, we generate nm samples and
expressions of d genes. Gene expressions are generated in
a way that all expressions have marginally normal distri-
butions with unit variance, and the correlation between
the expressions of genes i and j is 0.4|i-j|. In each dataset,BMC Bioinformatics 2009, 10:1 http://www.biomedcentral.com/1471-2105/10/1
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the first 20 genes are associated with the cancer outcome.
Specifically, for genes i = 1, ..., 20, the mean expressions of
the nm/2 cases (outcome Ym = 1) are generated randomly
from Uniform[l, u]. The mean expressions for the genes of
the controls (outcome Ym = 0) are zero. The mean expres-
sions for the genes not associated with the outcomes are
zero. The simulation setting here corresponds to the logis-
tic regression models for all three datasets. The regression
coefficients for the cancer-associated genes vary across
studies, which corresponds to different experimental set-
ups (for example different platforms) in different studies.
We consider combinations of the following simulation
settings: (1) sample size nm = 30 and 100; (2) number of
genes d = 100, 500 and 1000; and (3) different levels of
"signals" [l, u] = [0.5, 1.0] and [1.0, 1.5]. Thus, there are a
total of 12 different simulation scenarios.
We employ the proposed MTGDR, and tuning parameters
are selected via the 3-fold cross validation. For compari-
son, we also consider the following two alternative
approaches: (1) the pooled TGDR approach. Other than
the differences in regression coefficients (shifts of mean
expressions), the three datasets are generated in a compa-
rable manner. We pool all three datasets together, treat
them as if they were from a single experiment, and analyze
them with the TGDR approach; and (2) the meta analysis
approach based on individual TGDR analysis. We first
analyze each dataset using the TGDR approach. We then
search for genes identified in all three studies. This corre-
sponds to the meta analysis approach where each dataset
is analyzed separately using the TGDR and the results are
combined via a voting approach. We note that other alter-
native approaches exist. For example, it is possible to
replace the TGDR approach with the penalization
approaches discussed in [23]. Early studies have estab-
lished the comparable performance of the TGDR with
alternative approaches [19-21]. Since the proposed
MTGDR shares a similar thresholding paradigm with the
TGDR, we focus on the aforementioned two alternatives.
In Table 1, we show the mean (standard deviation) of the
number of identified genes and the number of true posi-
tives based on 200 replicates. We can see that (1) the pro-
posed MTGDR is capable of identifying the majority of the
genes truly associated with the outcome and has very
small false positive rates; (2) the performance of the
pooled analysis is less satisfactory but still acceptable. We
note that the three simulated datasets are more compara-
ble than those encountered in practical studies. The
regression coefficients differ across datasets, though the
differences are small. This comparability explains the rea-
sonable performance of the pooled analysis and should
not be expected in general with practical data; and (3) the
"individual TGDR + voting" meta analysis approach has
inferior performance, which is caused mainly by the small
sample size and the subsequent lack of reproducibility of
each individual dataset. We have also conducted simula-
tions under other settings and drawn similar conclusions
(results not shown).
Pancreatic cancer study
Data
Pancreatic ductal adenocarcinoma (PDAC) is a major
cause of malignancy-related deaths. Apart from surgery,
there is still no effective therapy, and even resected
patients die usually within one year postoperatively. Sev-
eral experiments have been conducted using microarrays
to identify pancreatic cancer genomic markers. In our
study, we gather and analyze four studies, which are first
reported in [24-27]. These four datasets have also been
analyzed by [28], and it has been argued that the clinical
settings in the four studies are comparable. Thus, it is rea-
sonable to conduct meta analysis with such data. We
Table 1: Simulation studies.
Pooled TGDR meta analysis MTGDR
nm d [l, u] Positive True pos. Positive True pos. Positive True pos.
30 100 [0.5, 1] 15 (2.2) 13 (1.7) 2 (1.3) 2 (1.3) 16 (1.8) 15 (1.8)
500 [0.5, 1] 17 (2.6) 13 (1.9) 2 (1.2) 2 (1.2) 15 (1.7) 14 (1.7)
1000 [0.5, 1] 19 (3.3) 13 (2.0) 2 (1.2) 2 (1.2) 16 (1.9) 14 (1.7)
30 100 [1, 1.5] 13 (2.0) 13 (1.9) 1 (1.0) 1 (1.0) 13 (2.0) 13 (2.0)
500 [1, 1.5] 14 (2.1) 10 (1.8) 1 (1.0) 1 (1.0) 14 (1.7) 14 (1.7)
1000 [1, 1.5] 14 (2.2) 12 (1.9) 1 (0.8) 1 (0.8) 15 (1.9) 14 (1.9)
100 100 [0.5, 1] 18 (1.7) 15 (1.5) 6 (1.9) 6 (1.9) 18 (1.8) 17 (1.5)
500 [0.5, 1] 21 (2.9) 16 (1.5) 5 (1.8) 5 (1.8) 19 (2.1) 18 (1.4)
1000 [0.5, 1] 22 (2.8) 16 (1.5) 5 (1.8) 5 (1.8) 19 (2.3) 17 (1.5)
100 100 [1, 1.5] 16 (1.5) 14 (1.5) 4 (1.5) 4 (1.5) 16 (1.7) 16 (1.7)
500 [1, 1.5] 18 (2.2) 14 (1.7) 4 (1.6) 4 (1.6) 16 (1.7) 15 (1.6)
1000 [1, 1.5] 14 (2.2) 12 (1.7) 4 (1.6) 4 (1.6) 17 (1.7) 16 (1.6)
Mean (standard deviation) of positive (number of genes selected by each approach) and true positive (number of selected genes that are truly 
cancer-associated) based on 200 replicates.BMC Bioinformatics 2009, 10:1 http://www.biomedcentral.com/1471-2105/10/1
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show the data descriptions in Table 2. Two of the four
studies use cDNA arrays, and two use oligonucleotide
arrays. Cluster ID and gene names are assigned to all of
the cDNA clones and Affymetrix probes based on Uni-
Gene Build 161. The two sample groups considered in our
analysis are PDAC and normal pancreatic tissues. Data on
chronic pancreatitis are available for [25,27], but will not
be used in our analysis.
For each dataset, data processing (including normaliza-
tion) has been separately conducted by researchers in each
individual study. We identity a consensus set of 2984 Uni-
Gene IDs. We remove genes with more than 30% missing-
ness in any of the four datasets. There are 1204 genes
remained for downstream analysis. For each data sepa-
rately, if Affymetrix is used, we first add a floor of 10 and
make log2 transformations of the expressions. We then fill
in missing values with medians across samples and stand-
ardize each gene expression to have zero mean and unit
variance.
MTGDR analysis
In the MTGDR analysis, tuning parameters are chosen via
the 3-fold cross validation. Fifteen genes are identified as
being associated with the risk of developing pancreatic
cancer. We show the gene IDs and corresponding esti-
mates in Table 3. We can see that if a gene has a nonzero
coefficient in one dataset, then it has nonzero coefficients
in all datasets (which indicates that this gene is identified
in all studies). We also note that the estimated coefficients
for one gene can be different across studies. This is the
extra flexibility allowed by the MTGDR over the pooled
analysis, which naturally accommodates differences
among experimental setups in different studies. Further-
more although the estimated coefficients may be different
for one gene across experiments, their signs are the same.
The same signs lead to similar biological conclusions (i.e.,
whether up-regulations of the genes are positively or neg-
atively associated with the risk of developing cancer).
We evaluate the biological implications of selected genes
by surveying [29] and other public databases. Among the
15 genes, several have been previously identified in inde-
pendent studies. Specifically, gene Hs.107 (Fibrinogen-
like 1) is a member of the fibrinogen family. In large scale
proteomic analysis of serum samples, certain members
from the fibrinogen family have been found to be over-
expressed in pancreatic cancer samples [30]. Gene
Hs.12068 (Carnitine acetyltransferase) is a key enzyme in
the metabolic pathway in mitochondria, peroxisomes,
and endoplasmic reticulum. CRAT catalyzes the reversible
transfer of acyl groups from an acyl-CoA thioester to car-
nitine and regulates the ratio of acylCoA/CoA in the sub-
cellular compartments. In addition, CRAT has been found
to be significantly under-expressed in PDAC samples [31].
Gene Hs.169900 (PABPC4) is localized primarily in the
cytoplasm. It may be necessary for the regulation of stabil-
ity of labile mRNA species in activated T cells. It is one of
the pancreatic cancer biomarkers identified in [26], where
it is down-regulated at least four-fold in four or more
PDAC specimens.
Gene Hs.180920 (RPS9 ribosomal protein S9) encodes a
ribosomal protein that is a component of the 40S subunit.
The protein belongs to the S4P family of ribosomal pro-
teins. Crnogorac-Jurcevic et al. [32] was the first to identify
the association between the dysregulated expression of
PRS9 and PDAC. Gene Hs.287820 (fibronectin 1)
encodes fibronectin, a glycoprotein present in a soluble
dimeric form in plasma and in a dimeric or multimeric
form at the cell surface and in the extracellular matrix.
Fibronectin plays an important role in maintaining the
structural integrity of the pulmonary epithelium and
endothelium. Decreases in serum fibronectin and
increases in pulmonary leukocyte margination during
acute pancreatitis may compromise the integrity of the air-
blood barrier and also increase the pulmonary uptake of
circulating pathogenic materials. Gene Hs.317432
(BCAT1) encodes the cytosolic form of the enzyme
branched-chain amino acid transaminase. This enzyme
catalyzes the reversible transamination of branched-
chain, alpha-keto acids to branched-chain, L-amino acids
essential for cell growth. It is one of the pancreatic cancer
markers broadly identified [33]. Gene Hs.5591 (MKNK1)
belongs to the MAPK pathway, which has been identified
to be associated with the development of multiple can-
cers. Protein encoded by gene Hs.62 (PTPN12) is a mem-
ber of the protein tyrosine phosphatase (PTP) family.
Table 2: Pancreatic cancer study: Data information.
Dataset P1 P2 P3 P4
Reference Logsdon Friess Iacobuzio-Donahue Crnogorac-Jurcevic
PDAC 10 8 9 8
N o r m a l 538 5
Array Affy. HuGeneFL Affy. HuGeneFL cDNA Stanford cDNA Sanger
UG 5521 5521 29621 5794
Reference: first author of the corresponding reference; PDAC: number of PDAC samples; Normal: number of normal samples; Array: type of array 
used; UG: number of unique UniGene clusters.BMC Bioinformatics 2009, 10:1 http://www.biomedcentral.com/1471-2105/10/1
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PTPs are known to be signaling molecules that regulate a
variety of cellular processes including cell growth, differ-
entiation, mitotic cycle, and oncogenic transformation. As
has been pointed out by [28], gene Hs.75335 (GATM) has
been identified as a pancreatic cancer marker in multiple
independent studies. Gene Hs.78225 (NBL1) is located at
chromosome 1p36. Deletion of material from this region
is common in ineuroblastoma. It is possible that a tumor
suppressor gene is present in this region.
Ideally, statistical evaluations of the MTGDR should be
based on independent data, though it is often unavaila-
ble. As an alternative, we conduct evaluations using the
following Leave-One-Out (LOO) approach, which has
been adopted extensively in cancer microarray studies. We
first remove one subject from the dataset. With the
reduced dataset, we compute the MTGDR estimate. We
note that, to get a relatively fair evaluation, a new set of
tuning parameters needs to be computed for the reduced
dataset. With the MTGDR, we are able to obtain one
regression model for each individual dataset. Then using
the model for the dataset that the removed subject
belongs to, we are able to predict the probability and class
membership (by dichotomizing the predicted probability
at 0.5) for the removed subject. We repeat this procedure
over all subjects and compute the classification error.
With the LOO approach, the MTGDR misclassifies 2 sub-
jects in data P3; otherwise, it achieves perfect classifica-
tion.
Analyses With Alternative Approaches
To facilitate a more comprehensive understanding of the
MTGDR approach and the pancreatic study, we conduct
the following additional analyses.
ANALYSIS WITH THE POOLED TGDR APPROACH
As in the simulation study, we ignore the fact that the four
datasets are from different studies that use different plat-
forms. We pool the four datasets and analyze them using
the TGDR approach. The sample size of the pooled dataset
is 56. A total of 22 genes are identified using this
approach. Specifically, this approach identifies 13 of the
15 genes identified by the MTGDR and misses genes
BCAT1 and NBL1. As discussed in the above section, both
of those two genes have important implications in pancre-
atic cancer development. (More detailed information on
gene identification using this approach is available upon
request.) We also evaluate performance of the pooled
approach using the LOO. Two subjects (1 in P3 and 1 in
P4) are not properly classified.
META ANALYSIS BASED ON INDIVIDUAL TGDR
We first analyze each dataset using the TGDR approach
and then search for genes identified in multiple studies.
This is a voting-based meta analysis approach. For the four
datasets, TGDR identifies 7 (P1), 10 (P2), 6 (P3), and 1
(P4) genes, respectively. The numbers of overlaps with
genes identified using the MTGDR are 1, 1, 2, and 0,
respectively. There is only 1 gene identified with both P2
and P3. Otherwise, there is no overlap between genes
identified with the four datasets. Genes identified in one
study cannot be used to satisfactorily predict subjects in
other studies. For example, we use genes identified in P2
and the corresponding logistic model to make predictions
for the rest of the three datasets. Four (P1), 6 (P3), and 4
(P4) subjects cannot be properly classified.
META ANALYSIS OF MARGINAL EFFECTS
With the MTGDR and the two alternative approaches, we
search for genes with joint  effects on pancreatic cancer
development. To provide a more comprehensive analysis
of the pancreatic data, we conduct the following analysis
of  marginal  effects. Since the pancreatic data have the
"normal versus cancer" binary setup, for each dataset and
each gene, we conduct the two-sample comparison of
expressions of normal versus cancer samples using the t-
Table 3: Pancreatic cancer study: MTGDR estimates and rank (in meta analysis of marginal effects).
UniGene Gene name P1 P2 P3 P4 Rank
Hs.107 Fibrinogen-like 1 -0.078 -0.074 -0.096 -0.062 1
Hs.12068 Carnitine acetyltransferase -0.265 -0.387 -0.189 -0.250 7
Hs.16269 B-cell CLL/lymphoma 7B 0.038 0.055 0.060 0.017 273
Hs.169900 PABPC4 -0.879 -0.992 -0.693 -0.775 15
Hs.180920 RPS9 ribosomal protein S9 -0.144 -0.244 -0.223 -0.189 53
Hs.241257 transforming growth factor beta binding protein 1 0.096 0.128 0.124 0.062 11
Hs.287820 Fibronectin 1 1.051 1.157 1.055 0.736 6
Hs.317432 BCAT1 -0.023 -0.012 -0.053 -0.022 144
Hs.5591 MKNK1 -0.082 -0.170 -0.149 -0.149 56
Hs.62 PTPN12 0.111 0.100 0.104 0.126 50
Hs.66581 Protein disulfide isomerase family A, member 2 -0.024 -0.028 -0.034 -0.013 3
Hs.75335 GATM -0.270 -0.259 -0.250 -0.250 2
Hs.76307 neuroblastoma, suppression of tumorigenicity 1 0.435 0.303 0.616 0.416 4
Hs.78225 NBL1 0.011 0.010 0.018 0.010 64
Hs.83383 Peroxiredoxin 4 -0.074 -0.094 -0.066 -0.085 5BMC Bioinformatics 2009, 10:1 http://www.biomedcentral.com/1471-2105/10/1
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test and compute the p-value. For each gene, we combine
the p-values across four studies using the Fisher's
approach [1]. We then rank genes using the p-values from
the meta analysis. Genes with smaller combined p-values
have smaller ranks. We note that this is the conventional
meta analysis approach for data with binary outcomes.
With this approach, we investigate the marginal associa-
tions between each individual genes and the cancer out-
come. We show the ranks for the MTGDR-identified genes
in Table 3. We can see that several MTGDR-identified
genes have very low ranks. Specifically, genes with mar-
ginal ranks 1–7 are identified using the MTGDR. How-
ever, there are also MTGDR-identified genes with very
high ranks. For example, genes Hs.317432, Hs.5591, and
Hs.62 have ranks 144, 56, and 50, respectively. Our anal-
ysis suggests that meta analysis and identification of genes
with joint effects cannot be replaced with meta analysis of
marginal effects.
Liver cancer study
Data
Gene expression profiling studies have been conducted on
hepatocellular carcinoma (HCC), which is among the
leading causes of cancer deaths in the world. We conduct
meta analysis using the four liver cancer microarray data-
sets described in [2]. Detailed data information is pro-
vided in Table 4, where the four datasets are referred to as
D1–D4, respectively. The four datasets were generated in
three different hospitals in South Korea. Although the
studies were conducted in a controlled setting, Choi et al.
[2] "failed to directly merge the data even after normaliza-
tion of each dataset."
In studies D1–D3, expressions of 10336 genes were meas-
ured. In study D4, expressions of 9984 genes were meas-
ured. We focus on the 9984 genes measured in all four
studies. For each dataset, the within-print-tip-group nor-
malization is first carried out. We then process the data as
follows:
(1) Un-supervised screening:
(1.1) if a gene has more than 30% of missingness in any
dataset, it is removed from downstream analysis. In total,
3122 out of 9984 genes pass this screening.
(1.2) if a subject has more than 30% missing expressions
for the 3122 genes, then this subject is removed. Eight
subjects are removed, leading to an effective sample size
of 125. We show the number of subjects actually used in
the analysis in Table 4.
(2) For each dataset, we fill in missing expression values
with medians across samples.
(3) Supervised screening: for each dataset, we compute
the two-sample t-statistic for each gene. We then assign a
rank to each gene based on the t-statistic. The overall rank
for one gene is defined as the sum of ranks across all four
datasets. One thousand genes with the lowest ranks are
selected for downstream analysis. This rank-based screen-
ing shares similar spirits as the one in [11].
(4) For each dataset, we normalize each gene expression
to have zero mean and unit variance.
Gene screening is conducted to exclude genes which are
very unlikely to be cancer-associated. Similar procedures
have been adopted in [20] and others.
MTGDR analysis
We employ the MTGDR approach with optimal tuning
parameters selected using the 3-fold cross validation.
Thirty-four genes are identified as being associated with
the risk of developing liver cancer. We provide informa-
tion and corresponding estimates for identified genes in
Table 5. We draw similar conclusions from Table 5 as
from Table 3. We note that, for a very small number of
genes, the signs of the four estimates are different. For
example, for gene 15.4.E1/Rab9 effector p40, three out of
four estimated coefficients are positive, and one is nega-
tive. The negative coefficient has a small absolute value
and can be caused by random variations. Different signs
may suggest conflicting biological conclusions. Without
having access to the original experimental setup or a gold
standard, we are unable to make further explanations of
the conflicting signs. Although those genes have been
identified with the MTGDR, they should be interpreted
with extreme caution because of those conflicting signs.
Table 4: Liver cancer study: Data Information.
Dataset D1 D2 D3 D4
Experimenter Hospital A Hospital B Hospital C Hospital C
# tumor 16 (14) 23 29 12 (10)
# normal 16 (14) 23 5 9(7)
Chip type cDNA(Ver.1) cDNA(Ver.1) cDNA(Ver.1) cDNA(Ver.2)
(Cy5:Cy3) sample:normal liver sample:placenta sample:placenta sample:sample
Tumor: number of tumor samples. Normal: number of normal samples. Numbers in the "()" are the number of subjects used in the analysis. Ver. 2 
chips have different spot locations from Ver. 1 chips.BMC Bioinformatics 2009, 10:1 http://www.biomedcentral.com/1471-2105/10/1
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We search public databases for independent evidence of
associations between identified genes and liver cancer
development. Among the identified genes, gene
KIAA0406 is one that constitutes the predictor of PI3
kinase activation. The PI3 kinase signaling pathway is
emerging as a promising therapeutic target in a number of
cancers as well as inflammation and heart diseases. It has
been found in a rat experiment that the mRNA and pro-
tein levels of Cyt19 are higher in the liver than in other tis-
sues. Gene Rab9 belongs to the RAS oncogene family,
which is activated in multiple cancers. ATPases are a class
of enzymes that catalyze the decomposition of adenosine
triphosphate (ATP) into adenosine diphosphate (ADP)
and a free phosphate ion. This dephosphorylation reac-
tion releases energy, which the enzyme (in most cases)
harnesses to drive other chemical reactions that would not
otherwise occur. RalGDS is an oncogene and can induce
transformation and gene expression by activating Ras, Ral,
and Rho mediated pathways. The combination of TPI and
an antitumor nucleoside, FTD, not only enhances the
antitumor efficacy and decreases the toxicity of FTD, but it
also suppresses TP-induced angiogenesis. Protein
encoded by ADFP is a major constituent of the globule
surface. Increases in mRNA levels are one of the earliest
indications of adipocyte differentiation. The Human G
protein-coupled receptor has been found expressed in
lung, heart, and lymphoid tumor tissues. MEN-1 is a can-
cer predisposition gene and has been found to be acti-
vated in pancreatic, ovarian, and male breast cancers.
Polyspecific organic cation transporters in the liver, kid-
ney, intestine, and other organs are critical for the elimi-
nation of many endogenous small organic cations as well
as a wide array of drugs and environmental toxins. Gene
SLC22A1 is one of three similar cation transporter genes
located in a cluster on chromosome 6. Mutations of gene
TUBB have been found in breast and non-small cell lung
cancers. Gene H2AFZ encodes a replication-independent
member of the histone H2A family that is distinct from
other members of the family. Studies in mice have shown
that this particular histone is required for embryonic
Table 5: Liver cancer datasets: MTGDR estimates and rank (in meta analysis of marginal effects)
Gene Information D1 D2 D3 D4 Rank
1.2.F.7/noseq/ -0.076 -0.100 -0.078 -0.035 340
1.3.A.8/clone MGC:5207 IMAGE:2901089 0.147 0.199 0.030 0.054 151
10.1.B.9/cDNA FLJ20844 fis, clone ADKA01904 -0.020 -0.016 -0.002 -0.002 556
11.3.F.6/noseq/ -0.275 -0.519 -0.225 -0.170 259
15.1.G.7/Cyt19 protein (Cyt19), mRNA 0.023 0.019 -0.001 0.009 144
15.2.D.10/EST387826 cDNA -0.041 -0.031 -0.003 -0.015 17
15.3.E.9/hypothetical protein MGC11287 0.016 0.034 0.015 0.014 131
15.4.E.1/Rab9 effector p40 (RAB9P40), mRNA 0.166 0.243 -0.012 0.083 315
17.2.B.11/ATPase, H+ transporting, lysosomal 9 kD 0.145 0.258 0.108 0.020 110
18.3.F.6/nomatch/ 0.072 0.073 0.070 0.045 501
19.1.G.5/Ras association (RalGDS/ 0.168 0.176 -0.036 0.042 472
2.2.E.11/triosephosphate isomerase 1 (TPI1), mRNA 0.012 0.012 0.004 0.011 59
2.2.G.10/UDP-glucose pyrophosphorylase 2 (UGP2) -0.296 -0.274 -0.043 -0.178 126
21.3.A.4/noseq/ 0.016 0.011 0.002 0.001 723
23.3.H.1/thioredoxin-like, 32 kD (TXNL) 0.285 0.226 0.066 0.033 252
25.2.A.5/noseq/ 0.016 0.014 0.001 0.009 974
26.2.D.2/adipose differentiation-related protein (ADFP) -0.169 -0.114 -0.219 -0.118 12
26.4.B.5/Human zyxin related protein ZRP-1 mRNA 0.161 0.127 0.042 0.070 118
3.2.E.10/Human G protein-coupled receptor V28 mRNA -0.707 -0.589 -0.359 -0.375 88
4.1.D.1/multiple endocrine neoplasia I (MEN1), mRNA -0.086 -0.075 -0.130 -0.090 22
4.2.H.5/solute carrier family 22, member 1 -0.014 -0.120 -0.144 -0.092 38
4.3.C.1/noseq/ -0.058 -0.020 -0.008 0.007 123
4.4.B.9/noseq/ -0.438 -0.670 -0.460 -0.502 3
5.1.A.9/noseq/ -0.001 -0.007 -0.002 -0.001 136
5.1.D.1/malate dehydrogenase 2, NAD (mitochondrial) 0.135 0.043 0.063 0.060 214
6.2.E.3/tubulin, beta polypeptide (TUBB), mRNA/ 0.024 0.012 0.004 0.011 33
6.3.B.3/noseq/ 0.104 0.104 -0.023 0.015 46
6.4.D.11/non-metastatic cells 2, protein expressed NME2 0.053 0.072 0.020 0.025 61
6.4.F.5/H2A histone family, member Z (H2AFZ), mRNA 0.047 0.062 -0.001 0.042 429
7.3.A.5/nomatch/ -0.329 -0.432 -0.297 -0.222 36
7.3.G.9/guanine nucleotide binding protein, q polypeptide 0.073 0.019 0.049 0.029 153
8.2.B.11/cystatin B (stefin B) (CSTB), mRNA 0.040 0.112 0.051 0.046 884
8.2.D.8/RNA helicase-related protein (RNAHP), mRNA -0.739 -1.369 -1.002 -1.140 1
8.3.A.7/proline-rich Gla polypeptide 2 -0.001 -0.019 -0.024 -0.026 37BMC Bioinformatics 2009, 10:1 http://www.biomedcentral.com/1471-2105/10/1
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development and revealed that the lack of functional his-
tone H2A can lead to embryonic lethality. This gene
encodes a member of the Asp-Glu-Ala-Asp (DEAD) box
protein family. Members of this family are believed to be
involved in embryogenesis, spermatogenesis, and cellular
growth and division.
We conduct statistical evaluations using the LOO
approach described above. The MTGDR misclassifies 6
(D1), 8 (D2), 4 (D3), and 2 (D4) subjects, respectively,
which leads to an overall classification error of 0.16. We
note that, supervised screening has been conducted prior
to analysis. To make a fair evaluation, in the LOO proce-
dure, we carry out the supervised screening for each
reduced data (with one subject removed) separately. The
possibility of overly optimistic evaluation can be mini-
mized.
Analyses with alternative approaches
As for the pancreatic study, we conduct the following
analyses using alternative approaches.
ANALYSIS WITH THE POOLED TGDR APPROACH
We pool the four datasets, which have a combined sample
size of 125, and analyze with the TGDR approach. This
pooled approach identifies 24 out of the 34 genes identi-
fied by the MTGDR, misses 10, and identifies 10 extra
genes not identified by the MTGDR. (Detailed informa-
tion on gene identification using this approach is availa-
ble upon request.) We also evaluate the performance of
this pooled approach using the LOO. Six (D1), 13 (D2),
11 (D3), and 6 (D4) subjects are not properly classified,
which leads to an overall classification error of 0.29.
META ANALYSIS BASED ON INDIVIDUAL TGDR
We analyze each individual dataset using the TGDR
approach and then search for overlaps of identified genes.
For the four datasets, the TGDR identifies 27 (D1), 10
(D2), 20 (D3), and 6 (D4) genes. The numbers of over-
laps with genes identified using the MTGDR are 4, 4, 3,
and 1. Among the identified genes, one is identified in
three datasets, another one is identified in two datasets,
and the remainder are identified in only one. Genes iden-
tified using one dataset cannot be used to make satisfac-
tory predictions for other datasets. For example, when
genes identified with D1 and the corresponding logistic
regression model are used to predict subjects in the rest of
the three datasets, 20 (D2), 8 (D3), and 6 (D4) subjects
cannot be properly classified.
META ANALYSIS OF MARGINAL EFFECTS
We conduct meta analysis of the marginal effects as
described in the pancreatic cancer study. In Table 5, we
show the marginal ranks of the MTGDR-identified genes.
A few MTGDR-identified genes also have very strong mar-
ginal effects. Specifically, genes with marginal ranks 1 and
3 are identified with the MTGDR. On the other hand,
there are several MTGDR-identified genes with very high
marginal ranks.
Conclusion
For many types of cancers, multiple microarray experi-
ments have been independently conducted to search for
genes associated with the same clinical outcomes. Early
studies have suggested that genes identified from the anal-
ysis of a single cancer microarray dataset may have low
reproducibility. Among the several possible causes are the
small sample sizes and lack of statistical power. A cost
effective solution is to pool multiple existing datasets with
similar study designs and conduct meta analysis. The mer-
its of meta analysis with cancer microarray data have been
established in many early studies and summarized in [6].
In this article, we have developed a new gene selection
method in the meta analysis of multiple cancer microar-
ray data.
In terms of methodology, the MTGDR differs significantly
from existing approaches. Compared to most existing
meta analysis approaches, the MTGDR focuses on the
selection of genes with joint effects on cancer and embeds
gene selection in estimation. Thus, it can complement
existing meta analysis of marginal effects and help to pro-
vide a more comprehensive description of the effects of
genes. When compared to pooled analysis, the MTGDR
allows for experiment-specific regression coefficients.
Such a strategy shares similar spirits as the random effects
approaches in conventional meta analysis. However,
existing random effects approaches are designed for data
with a small number of covariates and do not have built-
in gene selection mechanisms. The MTGDR advances
from such approaches by incorporating gene selection in
modeling. It can automatically accommodate different
experimental setups, especially different platforms. Com-
pared to intensity approaches that seek for transforma-
tions of gene expressions, the MTGDR does not need be
conducted on a case-by-case basis. In comparison to clas-
sic meta analysis approaches, the MTGDR pools and ana-
lyzes raw data instead of summary statistics and can be
more informative. In addition, the MTGDR puts more
emphasis on gene selection.
Our simulation studies suggest that the MTGDR outper-
forms the meta analysis approach based on an individual
dataset gene selection method. More specifically, it is
capable of identifying the same number or more of the
true positives with a lower false positive rate. In addition,
performance of the MTGDR is relatively insensitive to the
increase of the number of genes. Analyses of pancreatic
and liver cancer studies suggest that (a) the MTGDR is
capable of identifying a small number of genes that showBMC Bioinformatics 2009, 10:1 http://www.biomedcentral.com/1471-2105/10/1
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relatively consistent effects on cancer outcomes across
multiple studies; (b) many of the identified genes have
been confirmed in independent studies. The LOO evalua-
tion generates small classification errors; (c) the gene sets
identified by the MTGDR can be considerably different
from those identified by alternative approaches. Alterna-
tive approaches have inferior performance in terms of
inconsistency of identified genes across multiple studies
and larger classification errors; and (d) genes identified
using the MTGDR may differ significantly from genes with
low ranks in the meta analysis of marginal effects.
Despite its significant advancements over existing
approaches, our study may have the following limita-
tions. First, in the analysis of the liver data, inconsistent
signs for a small number of genes are observed. Such
inconsistency is not observed in the pancreatic data anal-
ysis or the simulation. It is possible to modify the MTGDR
algorithm and force the signs to be the same across multi-
ple studies. For example, for a specific gene, suppose that
one gradient is small and negative, and the other three
gradients are large and positive. We can add an additional
thresholding and set the negative gradient to be zero. We
choose to allow inconsistent signs, which may help raise
an alarm on the comparability of data and the applicabil-
ity of the proposed approach when such inconsistency is
observed. Second, in our data analysis, we are able to pro-
vide partial interpretations of the identified genes. Many
of these have been confirmed in independent studies.
However, for the liver cancer data, detailed information
on several identified genes is not available. Since the focus
of this study is to develop a new meta analysis approach,
we do not further pursue the biological implications of
the analysis results. Third, in the analysis, we evaluate the
performance of the MTGDR using the LOO approach.
With properly utilized cross validation, the evaluation
and comparison with other approaches are expected to be
reasonably fair. In standard logistic regression analysis,
when the sample size is much larger than the number of
genes, there are several other ways of evaluating the fitted
model and selected covariates. For example, p-values and
R2 can be computed. However, we note that the validity of
those evaluation criterions is established under the "sam-
ple size >> number of covariates" setting and is not appli-
cable to the microarray data, where the number of genes
is much larger than the sample size. To our best knowl-
edge, there is still no consensus on evaluation methods
with cancer microarray meta analysis.
Methods
Data and model
For simplicity of notation, we assume that the same set of
d genes are measured in all M different experiments with
M > 1. When different sets of genes are measured in differ-
ent experiments, the MTGDR is still applicable by setting
the expressions of missing genes as zero. Note that meta
analysis can be less powerful when the number of genes
measured in all studies decreases. For 1 ≤ m ≤ M, let Ym
denote the clinical outcomes and Zm denote the gene
expressions in the mth experiment. For each experiment,
we assume a regression model Ym ~ ϕ(Zm' βm), where βm is
the regression coefficient, Zm' denotes the transpose of Zm,
and ϕ is the known link function. By considering the joint
modeling of multiple genes, we are able to account for the
joint effects of genes on the clinical outcomes.
We assume the same link function ϕ  across different
experiments. This assumption has generally been made in
meta analysis. However, we allow for different regression
cofficients βmand, hence, different models under different
experiments. Such a strategy has been motivated by the
fixed effect models in meta analysis [10]. The rationale is
that a one unit gene expression change in experiment 1
(say, for example, a cDNA study) may not be equivalent
to a one unit change in experiment 2 (say, for example, an
Affymetrix study). The regression coefficients, which
measure the strength of associations, should be allowed to
differ.
We choose data with binary outcomes to describe the pro-
posed MTGDR. We note that this method is also applica-
ble to other types of cancer clinical outcomes, as long as
statistical models and objective functions can be properly
defined. For experiment m and binary outcome, Ym = 1
and Ym = 0 may denote the presence and absence of cancer
or two different cancer stages, respectively. We assume the
commonly used logistic regression model, which postu-
lates that the logit of the conditional probability
logit(P(Ym  = 1|Zm)) = αm  +  Zm'  βm, where αm  is the
unknown intercept.
Suppose that there are nm iid observations in experiment
m. The log-likelihood is:
Since the intercept αm is usually of little interest, for sim-
plicity, we rewrite Rm(αm, βm) as Rm(βm).
MTGDR method
The MTGDR is a gene selection method. It embeds gene
selection in the construction of regression models. Gene
selection then amounts to identifying the nonzero com-
ponents of the regression coefficients βm.
Under the present setup, it is natural to make the follow-
ing assumptions: (S1) The sets of genes with nonzero
coefficients (i.e., the identified cancer-associated genes)
are the same across different experiments. Under meta
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analysis, we expect certain comparability of multiple stud-
ies. Thus, although data generated under different experi-
ments are not directly comparable, the biological
conclusions should be comparable. In other words, we
should conclude that the same sets of genes are associated
with cancer across different experiments; (S2) Although
similar logistic regression models are used to link genes
with cancer outcomes in all experiments, the nonzero
components of the regression coefficients βm may be not
equal across experiments. This assumption is due mainly
to the concern of different experimental setups, especially
platforms.
Algorithm
Let β = (β1, ..., βM) and R(β) = R1(β1) + ... + RM(βM). Here
β is a d × M matrix. Let Δν be a small positive increment,
as in ordinary gradient descent searching. In the imple-
mentation of this algorithm, we choose Δν  = 10-3. Let
βm(ν) denote the parameter estimate of βm corresponding
to ν. Let 0 ≤ τ ≤ 1 be a fixed threshold value. The MTGDR
algorithm proceeds as follows.
1. Initialize β = 0 (component-wise) and ν = 0.
2. With current estimate β, compute the d × M negative
gradient matrix g(ν) = -∂R(β)/∂β, where the (j, m) element
of g is .
3. Compute the length d vector of meta gradient G, where
the jth component of G is .
4. Compute the meta threshold vector F(ν) of length d,
where the jth component of F(ν): Fj(ν) = I(|Gj(ν)| ≥ τ ×
maxl|Gl(ν)|) and I is the indicator function.
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Parameter paths as a function of k Figure 1
Parameter paths as a function of k. Dashed red line: simulated experiment 1; Dash-dotted blue line: simulated experiment 
2; Solid black line: simulated experiment 3. Vertical lines: cross-validated k.
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5. Update the (j, m) element of β: βj, m(ν + Δν) = βj, m(ν) -
Δνgj, m(ν)F(ν) and update ν by ν + Δν.
6. Steps 2–5 are iterated k times, where k is determined by
cross validation.
In Step 1, the MTGDR algorithm starts with the zero esti-
mates (i.e., no gene is identified as cancer-associated). In
Step 2, the gradients are computed for each individual
dataset. Genes with stronger effects on cancer outcomes
will have larger gradients. In Step 3, the meta gradient,
which is defined as the sum across different experiments,
is computed. It evaluates the overall effects of genes on
cancer outcomes across multiple experiments. For exam-
ple, consider that gene 1 shows only a large positive effect
in experiment 1 and no effects in other experiments,
whereas gene 2 shows moderate negative effects in all
experiments. Then the sum of gradients for gene 2, which
measures the overall effect across multiple experiments,
may be larger than that for gene 1. Gene 2 is thus more
likely to be selected since consistent effects are demon-
strated across experiments. In Step 4, a meta threshold
vector is computed. With this vector, when a gene is
selected, it is selected in all models across multiple exper-
iments. In Step 5, we update the MTGDR estimates for
only those selected genes. In addition, by allowing for dif-
ferent gradients across multiple studies, the MTGDR
allows for different estimates (and, hence, different mod-
els) for different experiments.
The tuning parameters τ and k jointly determine the prop-
erty of β and the property of gene selection. When τ ≈ 0, β
is dense even for small values of k (i.e, many genes are
selected). When τ ≈ 1, β is sparse for small k and remains
so for a relatively large number of iterations. But it will
become dense eventually. At the extreme, when τ = 1, the
MTGDR usually updates estimates for a single gene at
each iteration, which is similar to the stage-wise
approaches. When τ is in the middle range, the character-
istics of β are between those for τ = 0 and τ = 1. For τ ≠ 0,
gene selection can be achieved with cross-validated, finite
k by having certain components of β exactly equal to zero.
As can be seen, the MTGDR involves only simple calcula-
tions and can be programmed with many existing soft-
ware. In our study, research software has been developed
using R and is available at [34].
The MTGDR has been partly motivated by the TGDR [35].
The two approaches share a similar thresholding scheme.
However, the MTGDR differs significantly from the TGDR
by analyzing multiple datasets. When analyzing a single
dataset with the TGDR, the effect of a gene can be repre-
sented by a single number – its regression coefficient.
However, when multiple datasets are present, the effect of
a gene needs to be considered across multiple studies and
represented with a vector of regression coefficients.
Loosely speaking, the TGDR conducts the selection of
individual coefficients, whereas the MTGDR conducts the
selection of groups of coefficients. Although intuitively
simple, extension from individual selection to group
selection has been shown to be highly nontrivial.
Tuning parameter selection
We use the V-fold cross validation to select the optimal k
and τ. For τ = 0,0.05, ..., 0.95,1, we search over k to maxi-
mize the V-fold cross validation objective function, which
can be defined following [20]. With the V-fold cross vali-
dation, partial protection against over-fitting is also pro-
vided. In this study, we set V = 3, which is due mainly to
the small sample size consideration.
A graphic demonstration
We use the following numerical example to demonstrate
the MTGDR parameter paths. For m = 1, 2 and 3, we gen-
erate data from
.
In this simulated meta analysis, there are three independ-
ent experiments and four genes per experiment.  s are
generated independently and N(0,1) distributed. We set
β1 = (2.0, 2.0, 0,0), β2 = (1.5, 1.5, 0,0) and β3 = (1.0, 1.0,
0,0). In all three experiments, only the first two genes are
associated with the binary outcomes, and their corre-
sponding coefficients are different. We simulate 50 obser-
vations in each experiment.
The 3-fold cross validation select τ = 1.0 and k = 620. We
show in Figure 1 the parameter paths as a function of k for
τ  = 1.0. Individual parameter paths are similar to the
stage-wise paths. We can see that for any k, the estimated
coefficients for one gene are either all zero or all nonzero
across experiments. For a specific gene with nonzero coef-
ficients, the estimated coefficients are different across
experiments.
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